Silence Therapeutics Reports Narrower Losses on Reduced R&D Spend
Event summary
- Silence Therapeutics reported a net loss of $12.3M for Q2 2026, down from $27.4M in the same period last year.
- R&D expenses decreased by $8.4M YoY due to completion of zerlasiran Phase 3 readiness and reduced personnel costs.
- Divesiran showed durable efficacy results in the SANRECO Phase 1 trial for polycythemia vera, with data presented at EHA 2026.
- SLN312 (AZD1705) demonstrated favorable safety profile and dose-dependent reductions in ANGPTL3 protein levels in Phase 1 results presented at EAS 2026.
The big picture
Silence Therapeutics is navigating the challenging clinical-stage biotech landscape by cutting costs while advancing its siRNA pipeline. The company's focus on durable efficacy data for divesiran and SLN312 positions it competitively in hematology and cardiovascular markets, but sustained financial discipline will be key to long-term viability.
What we're watching
- Pipeline Progress
- Whether divesiran can maintain its best-in-class profile through Phase 2 trials and potential expansion into myelodysplastic syndrome.
- Financial Sustainability
- The pace at which Silence Therapeutics can extend its cash runway beyond the current $72.1M position.
- Collaboration Dynamics
- How AstraZeneca's involvement with SLN312 will impact future development and commercialization strategies.
Related topics